Advancing AMD screening with an offline, AI-powered smartphone-based fundus camera: A prospective, real-world clinical validation

利用离线式人工智能智能手机眼底相机推进AMD筛查:一项前瞻性真实世界临床验证

阅读:1

Abstract

OBJECTIVES: This study evaluated a novel offline, AI-driven age-related macular degeneration (AMD) screening algorithm against fundus image-only grading and the standard of care (combined Spectral Domain-Optical Coherence Tomography (SD-OCT) and fundus image grading). METHODS: Conducted prospectively at a South Asian tertiary eye hospital, this study utilized a validated smartphone-based non-mydriatic fundus camera to capture macula-centred images. The Medios AI's ability to detect referable AMD was compared to a reference standard image grading, using fundus images from the Zeiss Clarus 700 table-top camera and SD-OCT line scan across fovea. Three retina specialists provided blinded AMD diagnoses based on: (1) Zeiss Clarus 700 fundus images alone, and (2) combined SD-OCT and fundus images (standard of care). Referable AMD was defined as intermediate or advanced AMD. RESULTS: Among 984 eyes from 492 patients (mean age 61.8 ± 9.9 years), 52% had referable AMD. Inter-grader agreement was strong, with Cohen's Kappa scores of 0.81-0.84. The Medios AI's sensitivity and specificity for detecting referable AMD against fundus-only grading (n = 492) were 88.48% (95% CI: 84.04-92.03%) and 87% (95% CI: 81.86-91.11%), respectively. Against combined grading (n = 489), AI sensitivity was 90.62% (95% CI: 86.37-93.90%), and specificity was 85.41% (95% CI: 80.21-89.68%). False negatives were primarily intermediate AMD (71%), while 59% of false positives were early AMD. CONCLUSION: The novel, automated, offline AMD AI integrated on a smartphone fundus camera demonstrated robust performance in identifying referable forms of AMD, supporting its potential as an affordable and accessible screening solution.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。